TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC

This is a single-arm, open-label, dose-escalation clinical trial designed to evaluate the safety, tolerability, expansion, and persistence of TC-D101 CAR-T cells in patients with DLL3-positive Relapsed/Refractory primary small cell lung cancer(r/r SCLC) who have progressed after prior therapies. The primary objective is to determine the maximum tolerated dose (MTD), with a secondary aim to assess preliminary clinical efficacy in SCLC.

Trial Details

NCT ID
NCT07246304
Phase
EARLY_PHASE1
Sponsor
TCRCure Biopharma Ltd.
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • TC-D101 CAR-T
Locations (sample)
  • Nanjing, Jiangsu, China|32.06167,118.77778

Key Eligibility Criteria

  • Participants must voluntarily provide written informed consent.
  • Aged 18-75 years (inclusive).
  • Life expectancy ≥ 3 months.
  • ECOG performance status 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →